Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.20.4
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating expenses:    
Research and development $ 3,866,007 $ 1,408,148
General and administrative 1,997,986 1,060,906
Loss from operations (5,863,993) (2,469,054)
Foreign exchange loss (13,247)
Net loss $ (5,877,240) $ (2,469,054)
Share information:    
Net loss per share, basic and diluted $ (0.34) $ (0.44)
Weighted average shares outstanding, basic and diluted 17,218,485 5,591,894